Vitamin C, Vitamin B12, Folate and the Risk of Osteoporotic Fractures. A Case-Control Study

2007 ◽  
Vol 77 (6) ◽  
pp. 359-368 ◽  
Author(s):  
Martínez-Ramírez ◽  
Palma Pérez ◽  
Delgado-Martínez ◽  
Martínez-González ◽  
De la Fuente Arrillaga ◽  
...  
Keyword(s):  
Folic Acid ◽  
Vitamin C ◽  
Fracture Risk ◽  
Case Control Study ◽  
Serum Vitamin ◽  
Osteoporotic Fractures ◽  
Case Control ◽  
Vitamin B ◽  
Erythrocyte Folate ◽  
Control Study

Water-soluble vitamins influence the development of an adequate structure of bone tissue, but there is scant information relating them with osteoporotic fractures. We analyze whether serum vitamin C, vitamin B12, and erythrocyte folate, or dietary intake of vitamin C and folate, are related with osteoporotic fractures in the elderly. A hospital-based case-control study was carried out at the Hospital of Jaén (167 cases, 167 controls), Spain. Cases were defined as patients aged 65 or more years with a low-energy fracture. Controls were people without fracture, matched for age and sex with cases. Diet was assessed by a semi-quantitative food frequency questionnaire. Serum vitamin C was measured using high-performance liquid chromatography (HPLC). Folic acid and vitamin B12 were measured using procedures of competitive or immunometric immunoassay. Multivariable analyses were also fitted to adjust for confounding using analysis of covariance (for the comparison of adjusted means) and conditional logistic regression (for estimating adjusted odds ratios). A statistically significant difference between cases and controls for vitamin C blood levels was found, being higher for controls (p = 0.01). Analysis of the association between serum vitamin C and fracture risk showed a linear trend (p = 0.03) with a significantly reduced risk for the upper quartile (OR = 0.31; 95% CI 0.11–0.87). The intake of vitamin C, folic acid, and B12 was not related to fracture risk, nor was there any association with erythrocyte folate or serum vitamin B12. In conclusion, serum vitamin C levels were lower in cases with osteoporotic fractures than in controls.

scholarly journals The Relationship between Serum Levels of Vitamin C, Uric Acid and Antioxidant status with Coronary Artery Disease: a Case-Control Study

2020 ◽  
Author(s):  
Aida Torkzaban ◽  
Seyed Amir Mansour Alavi Naeini ◽  
Akbar Hassanzadeh ◽  
Mehrdad Namdari
Keyword(s):  
Uric Acid ◽  
Vitamin C ◽  
Antioxidant Status ◽  
Case Control Study ◽  
Demographic Data ◽  
Serum Vitamin ◽  
Serum Levels ◽  
Case Control ◽  
Significant Difference ◽  
Control Study

Abstract Background: Coronary Heart Disease (CHD) is among the main causes of death in adults. Increase of oxidative stress and defects in antioxidant defense play a major role in endothelium performance and are an effective factor in progress of atherosclerosis. The aim of this study is to measure the serum level of UA and vitamin C as well as the antioxidant status of CHD patients to evaluate their relationship and compare them with the healthy individual.Materials and methods: The present case-control study was performed on 44 cases and 44 controls. Demographic data and anthropometric indices were measured. Food frequency questionnaire (FFQ) and international physical activity questionnaire were also completed. After 12 hours of fasting, 10 ml blood was sampled from the participants. Uric acid (UA), vitamin C, TAC and MDA were also measured. The data were finally analyzed by SPSS Ver 22 software.Results: A significant difference was observed between the two groups in terms of uric acid (P<0.001) and vitamin C (P<0.03). However, mean MDA and TAC showed no significant difference between the two groups. The two groups’ difference in terms of vitamin A, E and beta carotene, zinc and selenium intake was not significant. A significant difference was however detected between the two groups in terms of vitamin C intake (P<0.047). A significant relationship was also observed between the systolic blood pressure and CHD (P<0.028).Conclusion: Our results suggest that increasing of serum uric acid and a decrease in serum vitamin C level can be considered as risk factors for CHD patients. Due to the lack of significant correlation between TAC and CHD in this study, it seems that different results will be obtained with increasing sample size.

scholarly journals Comparative case-control study of homocysteine, vitamin B 12 , and folic acid levels in patients with epilepsy

2017 ◽  
Vol 32 (7) ◽  
pp. 440-445
Author(s):  
L. Pulido Fontes ◽  
M. Pulido Fontes ◽  
P. Quesada Jiménez ◽  
J. Muruzabal Pérez ◽  
M. Mendioroz Iriarte
Keyword(s):  
Folic Acid ◽  
Case Control Study ◽  
Case Control ◽  
Vitamin B ◽  
Vitamin B 12 ◽  
Patients With Epilepsy ◽  
Control Study

Tamoxifen Use and Osteoporotic Fracture Risk: A Population-Based Analysis

2008 ◽  
Vol 26 (32) ◽  
pp. 5227-5232 ◽  
Author(s):  
Andrew L. Cooke ◽  
Colleen Metge ◽  
Lisa Lix ◽  
Heather J. Prior ◽  
William D. Leslie
Keyword(s):  
Fracture Risk ◽  
Osteoporotic Fracture ◽  
Case Control Study ◽  
Substantial Reduction ◽  
Osteoporotic Fractures ◽  
Population Based ◽  
Case Control ◽  
Mineral Density ◽  
Medical Diagnoses ◽  
Control Study

Purpose Although tamoxifen has been shown to increase bone mineral density in clinical trials, it is less clear whether this significantly affects fracture rates. Even fewer data are available on skeletal outcomes when tamoxifen is used outside of the context of a clinical trial. A population-based case-control study was undertaken to determine whether tamoxifen use is associated with osteoporotic fractures in routine clinical practice. Patients and Methods Population-based administrative data for the Province of Manitoba, Canada, were examined for tamoxifen use and nontraumatic fracture codes in women 50 years of age or older. Women with osteoporotic fractures (vertebral, wrist or hip; n = 11,096) from 1996 to 2004 were each compared with three controls without fracture, matched for age, ethnicity, and comorbidity (n = 33,209). Tamoxifen use was classified as never, past use, or current use. Results Lower osteoporotic fracture rates were associated with current tamoxifen use (univariate odds ratio [OR] = 0.68; 95% CI, 0.55 to 0.84). After controlling for demographic and medical diagnoses known to affect fracture risk, current use was associated with a significantly reduced overall osteoporotic fracture risk (adjusted OR = 0.68; 95% CI, 0.55 to 0.88) and of hip fractures (adjusted OR = 0.47; 95% CI, 0.28 to 0.77). Neither recent nor remote past tamoxifen use was associated with reduced osteoporotic fracture risk. Breast cancer was not independently associated with osteoporotic fractures (adjusted OR = 0.95; 95% CI, 0.81 to 1.12). Conclusion In a population-based case-control study, current tamoxifen use was associated with a substantial reduction in osteoporotic fractures.

Sign in / Sign up

Export Citation Format

Share Document